All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key takeaways and updates from SOHO 2023?
Key takeaways and updates from SOHO 2023
Firstly, Salles discusses the key session on follicular lymphoma (FL) which covered use of the Eastern Cooperative Oncology Group (ECOG) performance status, Follicular Lymphoma International Prognostic Index score, clinical parameters, and biological insights to predict outcomes in patient with FL. He then highlights the available treatments for patients experiencing disease progression within 24 months and the role of bispecific antibodies (mosenutuzumab, odronextamab, epcoritimab, and glofitamab) in FL. He concludes that monitoring patients with FL could help to identify a panel of mutations that explain the differences in response between patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Novel therapies for relapsed/refractory follicular lymphoma: Key updates from ICML 2023
A summary of updates from five key trials, including ROSEWOOD, TRANSCEND and ELM-2, on novel therapeutic agents for the treatment of patients with R/R FL,...
Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma
For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to chemotherapy and anti-CD20 immunotherapy, there...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox